Gaush Meditech Ltd (2407) Fair Value & Analysis
Healthcare · HK · Market cap HK$736M
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from HK$13.77 to HK$13.78 (+0.1%) since Aug 5, 2026. Share price −5.7% over the past month.
A solid business, screening 198% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$9.90). The market is more pessimistic than our downside scenario.
- Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (HK$9.90 to HK$17.96) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
44‑month range HK$4.57 – HK$48.87 · fair‑value band HK$9.90 – HK$17.96 · the HK$4.62 price screens below the HK$13.78 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Gaush Meditech Ltd (2407) currently trades at HK$4.62, while our model-based Fair Value estimate is HK$13.78, implying the stock looks roughly 198.3% undervalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Gaush Meditech Ltd generated revenue of HK$1.4B at a net margin of 7.0%. Revenue declined 7.5% year over year. It earns a return on equity of 5.6%. Net debt stands at HK$66.4M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$9.90 (bear case) to HK$17.96 (bull case); at HK$4.62, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at 198%, 2407 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Multiples (HK$11.54) versus Earnings-Based (HK$6.88). Highest evidence: Growth DCF (80).
Notify me when 2407 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 25
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Gaush Meditech Ltd. engages in research and development, production, and distribution of ophthalmic medical equipment and consumables, and the provision of technical services to end customers.
Full company description
Gaush Meditech Ltd. engages in research and development, production, and distribution of ophthalmic medical equipment and consumables, and the provision of technical services to end customers. The company's product portfolio comprising proprietary products, which it develops and manufactures, as well as distribution products of its brand partners, which it distributes, covering seven ophthalmology sub-specialties where ophthalmic medical devices are utilized for diagnosis, treatment, or surgeries, being vitreoretinal diseases, cataracts, refractive surgery, glaucoma, ocular surface diseases, optometry, and pediatric ophthalmology. The company was founded in 1998 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Gaush Meditech Ltd reported revenue of HK$1.4B in FY2025 versus HK$1.3B in FY2021, a compound +1.5%/yr. Reported net income was HK$96.2M in FY2025.
Watch 2407: get an alert when its fair value changes →
Peer Group
Medical Devices · 353 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Gaush Meditech Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gaush Meditech Ltd (2407) overvalued or undervalued?
What is the fair value of 2407?
What is the quality score of 2407?
What is the revenue of Gaush Meditech Ltd (2407)?
What is the net profit margin of 2407?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Gaush Meditech Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.